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ABSTRACT
Objectives: To determine whether pregnant women who have reactive hypoglycemia during the 100 g oral glucose toler-
ance test (OGTT) are at an increased risk of poor pregnancy outcomes.
Material and methods: We retrospectively analyzed perinatal data from 413 women who underwent a 3 h OGTT at 
24–28 weeks of gestation and gave birth in our clinics between January 2012 and December 2014. 
Results: According to OGTT results, the majority of the subjects were normoglycemic (n = 316, 76.5%), while 49 (11.9%) 
were diagnosed with gestational diabetes, and 33 (8.0%) had single high glucose values. Reactive hypoglycemia was de-
tected in only 15 patients (3.6%). The mean age of the women in the reactive hypoglycemia group was significantly lower 
than that of the women in the gestational diabetes and single high glucose value groups (26.4 ± 4.4 years, 31.4 ± 5.4 years, 
and 31.8 ± 4.3 years, respectively; p < 0.05). The newborns of the women in the reactive hypoglycemia group had higher 
rates of APGAR scores < 7, increased admission to the neonatal intensive care unit (NICU), and lower birth weights compared 
with the other groups (p < 0.001, p < 0.001, and p = 0.009, respectively).
Conclusion: Reactive hypoglycemia during the 3 h 100 g OGTT is significantly associated with low APGAR scores, low 
birth weights, and prenatal admission to the NICU. Therefore, pregnant women who develop hypoglycemia during the 
100 g OGTT performed at 24–28 weeks of gestation should receive attentive follow-up care to decrease the possibility of 
adverse perinatal outcomes. 
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INTRODUCTION
An evaluation for gestational diabetes mellitus (GDM) 
is widely performed between 24–28 weeks of gestation in 
women without pre-gestational diabetes. Two methods are 
commonly used: a one-step approach, the 75 g oral glucose 
tolerance test (OGTT); and a two-step approach, the 50-g 
glucose challenge test (GCT) followed by an 100 g OGTT if 
the threshold is exceeded. An estimated 95% of obstetric 
patients in the United States undergo sequential model uni-
versal screening for GDM using the two-step approach [1, 2].
Some women who have abnormal test results 
(≥ 140 mg/dL) on the 50 g GCT experience hypoglycemia 
during the 3 h 100 g OGTT, with symptoms including diz-
ziness, nausea, tachycardia, and perspiration, a condition 
known as reactive hypoglycemia [3, 4]. Concomitant blood 
samples may reveal very low blood glucose levels in the-
se women. There is no precise cut-off blood glucose level 
that can predict hypoglycemic symptoms. Some patients 
with normal glucose values may experience hypoglycemic 
symptoms, while others may not have any symptomatic 
indications of hypoglycemia, even at very low blood gluco-
se concentrations [5, 6]. However, various reports suggest 
a blood glucose level of 45–50 mg/dL (2.5–2.78 mmol/L) is 
indicative of reactive hypoglycemia [7–9].
Hypoglycemic symptoms or low blood glucose levels 
during the test may be sources of anxiety for both patients 
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and healthcare providers. Despite the known associations be-
tween elevated maternal glucose levels and adverse maternal 
and neonatal outcomes, the potential relationship between 
low maternal glucose levels during the 100 g OGTT and ad-
verse perinatal and neonatal outcomes remains unknown.
The aim of the present study was to determine whether 
pregnant women who have reactive hypoglycemia during 
the 100 g OGTT are at an increased risk for poor pregnancy 
outcomes, such as preterm delivery, cesarean delivery, pre-
eclampsia, small-for-gestational age (SGA) fetuses, increased 
birth weight, or low Apgar scores.
MATERIAL AND METHODS
Study design and population
We conducted a retrospective cohort study by reviewing 
the perinatal data of all women who underwent a 3 h OGTT 
and gave birth at the Obstetric and Clinics Department of 
Gaziosmanpasa University and Tokat State Hospital between 
January 2012 and December 2014. Women with single-
ton pregnancies who had abnormal 1 h 50 g GCT results 
(≥ 140 mg/dL) at 24–28 weeks of gestation and thus under-
went the 3 h 100 g oral GTT were included in the study [10]. 
The exclusion criteria were twin pregnancies, documented 
type I or II diabetes mellitus, multiple GCTs in the same 
pregnancy (only one entry per pregnancy was allowed), 
and incomplete medical records. A total of 421 women met 
the inclusion criteria. Eight women (1.9%) were excluded 
due to incomplete medical records; thus, 413 women were 
included in the study. 
The study was approved by the institutional ethics 
committee (Approval number: 14-KAEK-237, Registered 
date: 23.12.2014) and conducted in accordance with the 
latest version of the Declaration of Helsinki. The informed 
consent requirement was waived due to the retrospective 
design of the study. 
Study groups
Based on the OGTT results, patients were classified as 
follows: patients with reactive hypoglycemia (Group 1: pla-
sma glucose ≤ 45 mg/dL), patients with normoglycemia 
(Group 2: normal plasma glucose values), patients with only 
one abnormal glucose value (Group 3), and patients with 
GDM (Group 4: two or more high plasma glucose values).
In our clinic, we screen non-diabetic pregnancies for GDM 
at 24–28 weeks of pregnancy using a two-step standard 
protocol during a routine prenatal visit. This protocol is a 1 h 
50 g GCT, followed by a 3 h 100 g diagnostic OGTT if the GCT 
plasma glucose result is ≥140 mg/dL. GDM is diagnosed when 
two or more OGTT plasma glucose levels meet the criteria for 
a positive test as recommended by the National Diabetes Data 
Group (NDDG), which include plasma glucose thresholds of 
95 mg/dL for fasting, 180 mg/dL for 1 h, 155 mg/dL for 2h, 
and 140 mg/dL for 3 h OGTTs [11]. Reactive hypoglycemia is 
defined as a plasma glucose level of < 45 mg/dL (2.5 mmol/L) 
according to the 1986 Consensus Statement of the Third In-
ternational Symposium on Hypoglycemia [7]. Another reason 
for choosing this cut-off plasma glucose level (45 mg/dL) for 
hypoglycemia was that it was detected in less than 10% of 
our study population during OGTTs.
Study procedures
The following data were recorded from patients’ hospital 
files and compared among the study groups: demographics; 
results of fetal assessment tests, including fetal biometry; 
amniotic fluid index; gestational age at delivery; neonatal 
results, including APGAR scores; fetal birth weight; rates 
of admission to the neonatal intensive care unit (NICU); 
administration of phototherapy; and obstetrical results, 
including the mode of delivery and the presence of dysto-
cia. Large-for-gestational-age (LGA) status was deﬁned as 
a birth weight above the 90th percentile for age, and SGA 
was deﬁned as a birth weight below the 10th percentile for 
age [12]. Macrosomia was deﬁned as an estimated fetal 
weight of 4,000 g or more, regardless of gestational age 
[13]. All patients underwent ultrasound examinations before 
proceeding to the delivery ward. In accordance with the 
guidelines of the Ministry of Health of Turkey, we recom-
mend elective cesarean delivery to women with GDM and 
estimated fetal weights of 4,000 g or more and to women 
without GDM and estimated fetal weights of 4,500 g or more.
Statistical analysis
Statistical analysis was performed using the PASW so-
ftware package for Windows (Statistical Package for Social 
Sciences, Version 18.0, SPSS Inc., Chicago, Illinois, USA). The 
data collected were summarized using descriptive statistics 
(e.g., mean, standard deviation, range, frequency, and per-
centage). For a comparison of categorical variables betwe-
en study groups, a chi-square test was used. For multiple 
comparisons of continuous variables, analysis of variance 
(ANOVA) and the Scheffé post-hoc test were used. The sta-
tistical level of significance was set at p < 0.05.
RESULTS
According to the 100 g OGTT results, the majority of 
the 413 pregnant women were normoglycemic (n = 316, 
76.5%) and 33 (8.0%) had single high glucose values, whi-
le 49 (11.9%) were diagnosed with gestational diabetes 
(Tab. 1).  Reactive hypoglycemia was detected in only 15 pa-
tients (3.6%). 
Maternal and prenatal parameters
Regarding maternal and prenatal characteristics, only 
age and gestational week at delivery were significantly dif-
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ferent among the groups (p < 0.001 and p = 0.029, respec-
tively; Tab. 2). The mean age of the women in the reactive 
hypoglycemia group was significantly lower than that of 
the women in the gestational diabetes and the single high 
glucose value groups (26.4 ± 4.4 years, 31.4 ± 5.4 years, and 
31.8 ± 4.3 years, respectively; p < 0.05 for both, Tab. 2). Gesta-
tional week at delivery was significantly lower in the reactive 
hypoglycemia group than in the normoglycemia and gesta-
tional diabetes groups (37.2 ± 1.5 weeks, 38.5 ± 1.7 weeks, 
and 38.7 ± 1.7 weeks, respectively; p < 0.05 for both, Table II). 
However, other maternal parameters (gravida, parity, pre-
term delivery, preeclampsia, and cesarean section rate) were 
similar among the groups (Tab. 2). 
Perinatal parameters
In terms of perinatal results, the newborns of the women 
in the reactive hypoglycemia group had significantly lower 
mean APGAR scores than those born to the women in the 
other groups (8.3 ± 1.3, p = 0.006; Tab. 3). Additionally, the 
newborns of the women in the reactive hypoglycemia group 
had higher rates of APGAR scores < 7, admission to NICU, 
and lower birth weights, compared with the other groups 
(p < 0.001, p < 0.001, and p = 0.009, respectively; Tab. 3). On 
the other hand, neonatal gender and SGA and LGA rates 
were similar among the groups (Tab. 3).
DISCUSSION
The OGTT is a widely accepted and frequently perfor-
med test used to diagnose gestational diabetes in pregnant 
women. In the present study, we evaluated the pregnancy 
outcomes of women who had reactive hypoglycemia du-
ring the 3 h 100 g OGTT. Although it is widely known that 
a significant number of women experience symptomatic 
hypoglycemia during OGTT, there are limited reports on the 
prevalence and perinatal significance of reactive hypogly-
cemia during the 100 g OGTT. Weissman et al. , who defined 
hypoglycemia as ≤ 50 mg/dL, reported an incidence rate 
of 6.3% for reactive hypoglycemia during the test among 
805 pregnant women over a 3-year period [3]. They found 
a lower incidence of gestational diabetes in women who 
experienced reactive hypoglycemia. In the present study, we 
detected reactive hypoglycemia in only 15 out of 413 wo-
men (3.6%) during the 3 h 100 g OGTT. All hypoglycemic 
events occurred 3 h after glucose ingestion, and there were 
Table 1. Distribution of patients according to 100 g oral glucose tolerance test results
100 g OGTT result Number of patients (%)
Group 1 Reactive hypoglycemia(glucose ≤45 mg/dL) 15 (3.6%)
Group 2 Normoglycemia(all plasma glucose values are normal) 316 (76.5%)
Group 3 Single high glucose value(only one abnormal glucose value) 33 (8.0%)
Group 4 Gestational diabetes(two or more high plasma glucose values) 49 (11.9%)
Total 413 (100.0%)
OGTT — oral glucose tolerance test 
Table 2. Maternal and prenatal characteristics of the study groups
Maternal/prenatal parameters
Group 1
(reactive 
hypoglycemia)
(n = 15)
Group 2
(normo-glycemia)
(n = 316)
Group 3
(single high 
glucose value)
(n = 33)
Group 4
(gestational 
diabetes)
(n = 49)
p value
Age [years] 26.4 ± 4.4 28.2 ± 5.6 31.4 ± 5.4* 31.8 ± 4.3* < 0.001
Gravida 2.4 ± 1.1 2.4 ± 1.3 2.7 ± 1.1 2.9 ± 1.5 0.117
Parity 0.6 ± 0.9 0.6 ± 0.9 0.9 ± 0.9 0.8 ± 1.1 0.333
Gestational week at delivery 37.2 ± 1.5 38.5 ± 1.7* 38.5 ± 1.3 38.7 ± 1.7* 0.029
Preterm delivery 3 (20.0%) 19 (6.0%) 3 (9.1%) 5 (10.2%) 0.162
Preeclampsia 0 (0%) 4 (1.4%) 1 (3.3%) 3 (7.0%) 0.113
Cesarean section 42 (28.6%) 90 (28.5%) 11 (33.3%) 17 (34.7%) 0.795
Data are given as mean ± SD or n (%) 
*Significantly different from reactive hypoglycemia group (p < 0.05)
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no cases of fasting hypoglycemia (after fasting for at least 
8 h). In our population, the rate of gestational diabetes after 
a positive screening test was 11.9%, which is similar to the 
prevalence rate of 10.6–23.2% seen in the literature [14, 15].
The adverse effects of gestational diabetes on maternal 
and neonatal health are well-documented [16]. Women with 
even one abnormal 3 h 100 g OGTT value reportedly have 
an increased risk of poor neonatal outcomes [17]. Therefore, 
the presence of gestational diabetes is screened in the cli-
nical practice of obstetrics, and confirmed most commonly 
via OGTT, when indicated [18]. However, some patients 
experience reactive hypoglycemia during OGTT. Pregnant 
women are more prone to developing hypoglycemia due 
to pregnancy-related changes in their glycemic profiles, 
such as increased basal insulin and decreased glucagon 
secretion [19, 20]. In addition to these physiological changes, 
other mechanisms may play a role in the development of 
reactive hypoglycemia. Eik et al. suggested that reactive 
hypoglycemia was associated with increased levels of anti-
-inflammatory and proinflammatory cytokines in the blood 
[21]. In another study, Berlin et al. reported that patients with 
suspected postprandial hypoglycemia had increased beta-
-adrenergic sensitivity, and emotional distress [22]. 
A few studies have evaluated the effects of reactive hypo-
glycemia on perinatal and neonatal outcomes, with conflicting 
results [3, 4, 23–25]. Pugh et al. compared 436 pregnant wo-
men who developed hypoglycemia during GCT with 434 nor-
moglycemic pregnancies, and found that the hypoglycemic 
patients were significantly younger, had lower pre-pregnancy 
body mass indices, and were more likely to develop preec-
lampsia than normoglycemic women [4]. Langer et al. repor-
ted an association between maternal hypoglycemia and SGA 
[23]. Feinberg et al. found increased NICU admissions among 
pregnant women who experienced hypoglycemia during GCT 
[24]. On the other hand, Calfee et al. found no relationships 
between hypoglycemia on GCT and fetal growth restriction 
or other adverse perinatal consequences [25]. Weissman et 
al. even reported that reactive hypoglycemia was associated 
with favorable pregnancy outcomes, such as a lower rate of 
gestational diabetes, low birth weights, and cesarean delivery 
for macrosomia [3]. In the present study, we found that youn-
ger pregnant women were more likely to develop reactive 
hypoglycemia during the 3 h 100 g OGTT, which is significantly 
associated with adverse pregnancy outcomes, such as low 
APGAR scores, low birth weights, and prenatal admission to 
the NICU. As these associations with hypoglycemia were seen 
at the 3 h level, we recommend that the 3 h measurement 
be retained until the clinical significance of hypoglycemia in 
pregnancy is fully elucidated.
The main limitation of the present study was its retro-
spective design, which is associated with disadvantages 
such as selection bias, potential recording errors, and dif-
ficulty in controlling exposures and outcomes. This limita-
tion precluded us from reaching any definitive conclusion 
regarding the perinatal significance of reactive hypogly-
cemia during the 100 g OGTT. Furthermore, in our study 
population, the sample size of pregnant women with re-
active hypoglycemia was relatively low (n = 15), which also 
limited the power of the study. Nevertheless, this study is 
one of only a handful in the literature providing evidence of 
the perinatal effect of reactive hypoglycemia. On this basis, 
further large-scale prospective studies are needed to clarify 
the maternal and perinatal effects of reactive hypoglycemia 
during the 100 g OGTT.
CONCLUSIONS
Although the prevalence of reactive hypoglycemia du-
ring the 3 h 100 g OGTT is relatively low, it is significantly 
associated with low APGAR scores, low birth weights, and 
prenatal admission to the NICU. Therefore, pregnant women 
Table 3. Perinatal outcomes of the study groups
Perinatal parameters
Group 1
(reactive 
hypoglycemia)
(n = 15)
Group 2
(normo-glycemia)
(n = 316)
Group 3
(Single high 
glucose value)
(n = 33)
Group 4
(Gestational 
diabetes)
(n = 49)
p value
Apgar 5 min 8.3 ± 1.3 9.0 ± 0.8* 8.6 ± 1.6 8.8 ± 0.6 0.006
Apgar < 7 (5 min) 3 (20.0%) 6 (1.9%)* 0 (0%)* 1 (2.0%)* < 0.001
Weight [g] 2852.0 ± 544.6 3282.4 ± 452.8* 3290.6 ± 510.5* 3443.7 ± 468.5* < 0.001
Male 8 (53.3%) 155 (49.2%) 19 (57.6%) 23 (46.9%) 0.782
NICU admission 4 (26.7%) 29 (9.2%)* 6 (18.2%) 11 (22.4%) 0.009
SGA 3 (20.0%) 17 (5.4%) 3 (9.1%) 2 (4.1%) 0.100
LGA 0 (0%) 9 (2.8%) 1 (3.0%) 2 (4.1%) 0.339
DM — diabetes mellitus; NICU — neonatal intensive care unit; SGA —small-for-gestational age; LGA — large-for-gestational age 
Data are given as mean ± SD or n (%) 
*Significantly different from reactive hypoglycemia group (p < 0.05)
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who develop reactive hypoglycemia during the 100 g OGTT 
performed at 24–28 weeks of gestation should be followed 
up closely, and care should be taken to prevent adverse 
perinatal outcomes. Further studies are needed to explore 
the mechanisms underlying the relationship between reac-
tive hypoglycemia and adverse perinatal outcomes, and its 
implications for clinical practice.
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